Curative Biotechnology, Inc. announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a part of the National Institutes of Health (NIH). Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute and Curative Biotechnology, Inc. will collaborate to evaluate Curative's proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.